Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Taysha Gene Therapies 1Q 2026 Earnings Call - FDA open to 6-month BLA if totality of evidence supports durability
Taysha walked investors through a crisp clinical and CMC sprint aimed at a potential expedited biologics license application for TSHA-102 in Rett syndrome. The company says FDA meetings left the door ...
- FDA meetings: Taysha held a Breakthrough Therapy Type B multidisciplinary meeting and a Type C meeting, and reports constructive FDA dialogue on pivotal design, endpoints, and BLA submission scenarios.
- 6-month BLA option: The FDA signaled the 6-month interim as an option, but approval will depend on the totality of evidence and the agency's comfort with durability—data will decide.
- PPQ campaign started: Taysha initiated its BLA-enabling process performance qualification campaign in April using the commercial TSHA-102 process, with execution expected to complete by Q4 2026.
- +12 more takeaways
Adient Q2 FY2026 Earnings Call - Modest guidance bump as China wins and onshoring offset $35M input-cost shock
Adient delivered a steady quarter: revenue rose 7% year over year to $3.9 billion, helped by FX and underlying volume gains, while adjusted EBITDA slipped to $223 million amid launch costs, temporary ...
- Sales of $3.9 billion in Q2, up 7% year over year, driven by favorable FX and underlying volume gains.
- Adjusted EBITDA was $223 million, down year over year due to launch costs, customer-driven production inefficiencies, and mix shifts.
- Adjusted net income was $41 million, or $0.52 per share.
- +12 more takeaways
SharkNinja Q1 2026 Earnings Call - AI-Driven Culture Fuels Double-Digit Growth and Raised Full-Year Outlook
SharkNinja delivered a blistering Q1 2026, posting 15.6% net sales growth to $1.41 billion and raising its full-year outlook across sales, adjusted EPS, and adjusted EBITDA. The company’s outperforman...
- Net sales surged 15.6% year-over-year to $1.41 billion, with domestic sales up 8.4% and international sales accelerating sharply to 31.6% growth.
- The company raised its full-year 2026 outlook, now expecting net sales growth of 11.5% to 12.5%, up from the previous 10% to 11% guidance.
- Adjusted EBITDA grew 17.5% year-over-year to $235 million, expanding margins by approximately 30 basis points to 16.7% despite tariff headwinds.
- +7 more takeaways
Instacart Q1 2026 Earnings Call - AI-Powered Growth and Advertising Expansion Drive Record Revenue
Instacart delivered a strong start to 2026, surpassing $10 billion in quarterly gross transaction value (GTV) and $1 billion in total revenue for the first time. The company reported 13% GTV growth an...
- Instacart surpassed $10 billion in quarterly GTV and $1 billion in total revenue for the first time, reflecting 13% and 14% year-over-year growth respectively.
- Advertising and other revenue grew 16% year-over-year, the fastest pace since Q3 2023, driven by broad-based strength across large, mid-market, and emerging brands.
- Adjusted EBITDA rose 23% to $300 million, with operating cash flow of $268 million and free cash flow of $253 million, despite a one-time $60 million regulatory settlement.
- +7 more takeaways
Postal Realty Trust Q1 2026 Earnings Call - Accelerating Acquisitions on Strong Visibility and Leverage
Postal Realty Trust is moving from a cautious accumulation phase to an aggressive expansion mode. The company raised its 2026 acquisition guidance to $130 million-$140 million, up from $115 million, d...
- Raised 2026 acquisition guidance to $130 million-$140 million, up $15 million, fueled by a 70% stock price appreciation and improved capital access.
- Provided rare forward-looking 2027 same-store cash revenue guidance of 6.5% growth, highlighting exceptional visibility into a single-tenant portfolio.
- Portfolio lease structure is maturing rapidly; the share of leases with annual rent escalators will surge from 3% in 2022 to 53% by 2027.
- +7 more takeaways
BrightView Holdings Q2 2026 Earnings Call - Land Revenue Inflection Drives Raised Guidance
BrightView Holdings delivered a pivotal second quarter, marking the long-awaited inflection in its Landscape Maintenance segment with 4% year-over-year revenue growth. The result validates a 30-month ...
- Landscape Maintenance revenue grew 4% year-over-year, marking the first YoY increase since Q3 2023 and validating the long-delayed inflection in the company’s recurring revenue engine.
- Customer retention improved to 85%, up from a 2023 low of 79%, with 35% of branches now achieving best-in-class 90%+ retention levels.
- The net new sales contract book expanded 3%, driven by a combination of improved retention and an accelerated sales force ramp, creating a $1.15 billion base for future growth.
- +7 more takeaways
Genworth Financial Q1 2026 Earnings Call - Enact Fuels Capital Returns as CareScout Scales Into Senior Living
Genworth Financial reported a modest $47 million net income in Q1 2026, but the real story lies in its strategic pivot. Excluding the volatile Closed Block, adjusted operating income hit $109 million,...
- Genworth redefines its reporting: Consolidated adjusted operating income excluding the Closed Block was $109 million in Q1 2026, isolating the core performance of Enact and corporate activities from legacy volatility.
- Enact remains the cash engine: The 81% owned subsidiary delivered $140 million in adjusted operating income, driven by a $39 million pre-tax reserve release and higher investment income.
- Capital returns are accelerating: Genworth received $99 million from Enact in Q1. Full-year expectations are $405 million from Enact, with $195-$225 million allocated to share repurchases and debt reduction.
- +7 more takeaways
Cencora Inc Q2 2026 Earnings Call - EPS Guidance Raised Amid Revenue Slowdown and OneOncology Integration
Cencora delivered a resilient second quarter with adjusted diluted EPS of $4.75, marking 7.5% growth and prompting an upward revision to full-year EPS guidance to $17.65-$17.90. Consolidated revenue r...
- Adjusted diluted EPS of $4.75 grew 7.5%, beating prior expectations and driving a full-year EPS guidance increase to $17.65-$17.90.
- Consolidated revenue hit $78.4 billion, up 4%, with U.S. Healthcare Solutions up 3% and International Healthcare Solutions up 13% on an as-reported basis.
- Gross profit expanded 16% to $3.4 billion, with margin improving 45 basis points to 4.31%, largely benefiting from the OneOncology acquisition.
- +7 more takeaways
Rayonier Advanced Materials (RYAM) Q1 2026 Earnings Call - Strategic Review Launches Amid Shifting Pulp Dynamics
Rayonier Advanced Materials (RYAM) reported a transition quarter marked by strategic uncertainty and operational pivots. The company launched a formal review of strategic alternatives, engaging Morgan...
- Strategic Alternatives Review Initiated: RYAM has engaged Morgan Stanley to explore a broad range of options, including partnerships, mergers, asset sales, and capital structure changes, while searching for a permanent CEO.
- Q1 2026 Adjusted EBITDA of $8 Million: The quarter fell short of full-year targets but met near-term expectations, highlighting the ongoing transition in the company's earnings profile.
- Cellulose Pricing Surge: Average cellulose sales prices rose 17% year-over-year, reflecting successful commercial actions to assert leadership and improve pricing power in a tight market.
- +7 more takeaways
Marriott International Q1 2026 Earnings Call - Broad-Based U.S. Strength Offsets Middle East Headwinds, Raises Full-Year RevPAR Guidance
Marriott International delivered a robust first quarter, with global RevPAR rising 4.2% and financial results landing at the top end of guidance. The U.S. and Canada showed broad-based strength across...
- Global RevPAR rose 4.2% in Q1 2026, with results at the top end of guidance.
- U.S. and Canada RevPAR grew 4%, driven by broad strength across all chain scales.
- Select service RevPAR in the U.S. and Canada increased 3.5%, a sharp turnaround from Q4’s 1% decline.
- +17 more takeaways